| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| MousePheno | abnormal ophthalmic nerve morphology | 1.84e-05 | 4 | 25 | 2 | MP:0009798 | |
| Domain | EGF_extracell | 1.46e-04 | 60 | 32 | 3 | IPR013111 | |
| Domain | EGF_2 | 1.46e-04 | 60 | 32 | 3 | PF07974 | |
| Domain | TIL_dom | 2.55e-04 | 14 | 32 | 2 | IPR002919 | |
| Domain | Disintegrin_CS | 3.36e-04 | 16 | 32 | 2 | IPR018358 | |
| Domain | ADAM_CR | 4.28e-04 | 18 | 32 | 2 | PF08516 | |
| Domain | - | 5.30e-04 | 20 | 32 | 2 | 4.10.70.10 | |
| Domain | Disintegrin | 5.85e-04 | 21 | 32 | 2 | PF00200 | |
| Domain | DISIN | 5.85e-04 | 21 | 32 | 2 | SM00050 | |
| Domain | EGF_3 | 6.66e-04 | 235 | 32 | 4 | PS50026 | |
| Domain | EGF-like_dom | 8.27e-04 | 249 | 32 | 4 | IPR000742 | |
| Domain | EGF_1 | 9.03e-04 | 255 | 32 | 4 | PS00022 | |
| Domain | ACR | 9.72e-04 | 27 | 32 | 2 | SM00608 | |
| Domain | ADAM_Cys-rich | 9.72e-04 | 27 | 32 | 2 | IPR006586 | |
| Domain | EGF-like_CS | 9.85e-04 | 261 | 32 | 4 | IPR013032 | |
| Domain | EGF_2 | 1.04e-03 | 265 | 32 | 4 | PS01186 | |
| Domain | Peptidase_M12B_N | 2.03e-03 | 39 | 32 | 2 | IPR002870 | |
| Domain | Pep_M12B_propep | 2.03e-03 | 39 | 32 | 2 | PF01562 | |
| Domain | DISINTEGRIN_1 | 2.13e-03 | 40 | 32 | 2 | PS00427 | |
| Domain | Reprolysin | 2.13e-03 | 40 | 32 | 2 | PF01421 | |
| Domain | ADAM_MEPRO | 2.13e-03 | 40 | 32 | 2 | PS50215 | |
| Domain | DISINTEGRIN_2 | 2.13e-03 | 40 | 32 | 2 | PS50214 | |
| Domain | Peptidase_M12B | 2.13e-03 | 40 | 32 | 2 | IPR001590 | |
| Domain | Disintegrin_dom | 2.24e-03 | 41 | 32 | 2 | IPR001762 | |
| Domain | PSI | 2.57e-03 | 44 | 32 | 2 | IPR016201 | |
| Domain | TPR_REGION | 2.78e-03 | 165 | 32 | 3 | PS50293 | |
| Domain | TPR | 2.78e-03 | 165 | 32 | 3 | PS50005 | |
| Domain | PSI | 2.81e-03 | 46 | 32 | 2 | SM00423 | |
| Domain | TPR_2 | 3.31e-03 | 50 | 32 | 2 | PF07719 | |
| Domain | TPR_2 | 3.31e-03 | 50 | 32 | 2 | IPR013105 | |
| Domain | TPR_8 | 3.71e-03 | 53 | 32 | 2 | PF13181 | |
| Domain | - | 5.25e-03 | 207 | 32 | 3 | 1.25.40.10 | |
| Domain | TPR-like_helical_dom | 7.28e-03 | 233 | 32 | 3 | IPR011990 | |
| Domain | EGF | 7.45e-03 | 235 | 32 | 3 | SM00181 | |
| Domain | MetalloPept_cat_dom | 8.47e-03 | 81 | 32 | 2 | IPR024079 | |
| Domain | - | 8.47e-03 | 81 | 32 | 2 | 3.40.390.10 | |
| Domain | EGF_CA | 9.50e-03 | 86 | 32 | 2 | PF07645 | |
| Pubmed | Human beta-tryptase is a ring-like tetramer with active sites facing a central pore. | 8.20e-07 | 2 | 32 | 2 | 9521329 | |
| Pubmed | The structure of the human betaII-tryptase tetramer: fo(u)r better or worse. | 8.20e-07 | 2 | 32 | 2 | 10500112 | |
| Pubmed | Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. | 8.20e-07 | 2 | 32 | 2 | 2187193 | |
| Pubmed | Characterization of a tryptase mRNA expressed in the human basophil cell line KU812. | 8.20e-07 | 2 | 32 | 2 | 8434231 | |
| Pubmed | 8.20e-07 | 2 | 32 | 2 | 15567416 | ||
| Pubmed | 8.20e-07 | 2 | 32 | 2 | 10391906 | ||
| Pubmed | The human mast cell tryptase tetramer: a fascinating riddle solved by structure. | 8.20e-07 | 2 | 32 | 2 | 10708850 | |
| Pubmed | Cloning and characterization of a second complementary DNA for human tryptase. | 8.20e-07 | 2 | 32 | 2 | 2203827 | |
| Pubmed | 8.20e-07 | 2 | 32 | 2 | 17449330 | ||
| Pubmed | 8.20e-07 | 2 | 32 | 2 | 31337736 | ||
| Pubmed | 8.20e-07 | 2 | 32 | 2 | 10898108 | ||
| Pubmed | Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3. | 2.46e-06 | 3 | 32 | 2 | 9920877 | |
| Pubmed | 2.46e-06 | 3 | 32 | 2 | 20410128 | ||
| Pubmed | 2.46e-06 | 3 | 32 | 2 | 9461614 | ||
| Pubmed | 2.46e-06 | 3 | 32 | 2 | 19748655 | ||
| Pubmed | Thioredoxin mediates oxidation-dependent phosphorylation of CRMP2 and growth cone collapse. | 4.92e-06 | 4 | 32 | 2 | 21521879 | |
| Pubmed | 8.19e-06 | 5 | 32 | 2 | 10843716 | ||
| Pubmed | New developments in the genetics and activation of mast cell proteases. | 1.23e-05 | 6 | 32 | 2 | 12217407 | |
| Pubmed | A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. | 3.70e-05 | 205 | 32 | 4 | 12040188 | |
| Pubmed | Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. | 7.76e-05 | 248 | 32 | 4 | 24006456 | |
| Pubmed | ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1. | 9.08e-05 | 1201 | 32 | 7 | 35696571 | |
| Pubmed | 2.24e-04 | 24 | 32 | 2 | 31740596 | ||
| Pubmed | 2.29e-04 | 329 | 32 | 4 | 17474147 | ||
| Pubmed | 2.84e-04 | 27 | 32 | 2 | 23624557 | ||
| Pubmed | 4.79e-04 | 35 | 32 | 2 | 32504627 | ||
| Interaction | DEFB109B interactions | 2.95e-05 | 38 | 32 | 3 | int:DEFB109B | |
| Interaction | FBXO2 interactions | 4.01e-05 | 411 | 32 | 6 | int:FBXO2 | |
| Cytoband | 1q32 | 5.42e-04 | 49 | 32 | 2 | 1q32 | |
| GeneFamily | ADAM metallopeptidase domain containing|CD molecules | 4.43e-04 | 27 | 21 | 2 | 47 | |
| GeneFamily | Tetratricopeptide repeat domain containing|Bardet-Biedl syndrome associated|BBSome | 7.78e-03 | 115 | 21 | 2 | 769 | |
| CoexpressionAtlas | Ectoderm Differentiated Cells_vs_Pluripotent Stem Cells-Confounder_removed-fold2.0_adjp0.05 | SEMA3A LRP2 MICAL1 TMTC2 ADAM11 ANGPTL2 RWDD2A TTC28 CEMIP2 DYRK1B | 3.77e-05 | 1466 | 32 | 10 | PCBC_ratio_ECTO_vs_SC_cfr-2X-p05 |
| CoexpressionAtlas | geo_heart_top-relative-expression-ranked_500_k-means-cluster#5 | 6.13e-05 | 8 | 32 | 2 | geo_heart_500_K5 | |
| CoexpressionAtlas | Ectoderm Differentiated Cells_vs_Mesoderm Day 5-Confounder_removed-fold2.0_adjp0.05 | 7.12e-05 | 967 | 32 | 8 | PCBC_ratio_ECTO_vs_MESO-5_cfr-2X-p05 | |
| CoexpressionAtlas | Ectoderm Differentiated Cells_vs_Endoderm Differentiated Cells-Confounder_removed-fold2.0_adjp0.05 | 1.49e-04 | 1075 | 32 | 8 | PCBC_ratio_ECTO_vs_DE_cfr-2X-p05 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Endothelial|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.53e-07 | 193 | 32 | 5 | 826b8dd801298b3e0cd76232feae5a14026b8806 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.53e-07 | 193 | 32 | 5 | 87d3a577d37fb0cb4b6313c596310de452bc3872 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.53e-07 | 193 | 32 | 5 | d485634c564b268e344b6a2863c26f6adaec9e38 | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-13|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 3.38e-06 | 144 | 32 | 4 | b2a9f3b5dd46d27689467f4a5fd717cd5827821f | |
| ToppCell | Children_(3_yrs)-Immune-mast_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 4.07e-06 | 151 | 32 | 4 | bbf735c6433c3fc2feedb24ed6f48c51d545fb60 | |
| ToppCell | renal_cortex_nuclei-Adult_normal_reference-Immune-Myeloid-Granulocytic-Mast_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 5.65e-06 | 164 | 32 | 4 | 2c48c6e4eeee845f0563982d0bfa2a176ca5ef61 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.3.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 6.22e-06 | 168 | 32 | 4 | 55f328353119cbdc521c782ebb8d163876f4186d | |
| ToppCell | COVID-19-lung-MAST|lung / Disease (COVID-19 only), tissue and cell type | 6.51e-06 | 170 | 32 | 4 | e90f18e5462381b38e918442b38b1c8105291908 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_atypical-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 6.98e-06 | 173 | 32 | 4 | 23248019c819f6e38337dcc4edb763ef1992e89e | |
| ToppCell | Mild/Remission-B_naive-8|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 6.98e-06 | 173 | 32 | 4 | 694d02c4d2dc2de4b344544f9124fec40fcf7d8f | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_atypical|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 6.98e-06 | 173 | 32 | 4 | f135cc9dcf34f33ced3210171ab40ae6d77cfae0 | |
| ToppCell | COVID-19-lung-MAST|COVID-19 / Disease (COVID-19 only), tissue and cell type | 7.47e-06 | 176 | 32 | 4 | 473c45a381ca109207d66ed1635668b391ea0e1f | |
| ToppCell | 3'-Child09-12-SmallIntestine-Hematopoietic-Myeloid-Mast_cell|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.81e-06 | 178 | 32 | 4 | c6704fcd21a9d2fe45679a1d998f04213b3bf224 | |
| ToppCell | Thalamus-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Slc17a6-Rora-Excitatory_Neuron.Slc17a6.Rora.C1ql2_(Anterodorsal_thalamic_nucleus)|Thalamus / BrainAtlas - Mouse McCarroll V32 | 7.91e-06 | 54 | 32 | 3 | 8a8abf565ea657bf16059c51a63534ede3d7ac12 | |
| ToppCell | droplet-Liver-LIVER_HEP|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.16e-06 | 180 | 32 | 4 | 423454e3390080ae03bb3cbb267255ebfe4df080 | |
| ToppCell | droplet-Liver-LIVER_HEP-30m|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.16e-06 | 180 | 32 | 4 | dd1b10c7f5a0fbc63163844ca1882884a24a84d3 | |
| ToppCell | PBMC-Convalescent-Lymphocyte-B-B_cell-B_naive-B_naive-2|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 8.34e-06 | 181 | 32 | 4 | 75035a3211e524bb659b82e6979f7d3a3121ae70 | |
| ToppCell | (4)_B_cells-(4)_B_mantle|(4)_B_cells / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 8.71e-06 | 183 | 32 | 4 | 21b7fb6482eb1d5d31a4029e47e0992e8ddc8e2c | |
| ToppCell | Smart-seq2-tissue-resident_(Smart-seq2)-myeloid-myeloid_granulocytic-mast_cell|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 9.09e-06 | 185 | 32 | 4 | 3fafb1d36c5f98a29d20a5ce5192c83d6f603514 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.0.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.29e-06 | 186 | 32 | 4 | f690e26b2ed024bd8ede494b8e9a00976fdc9734 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.49e-06 | 187 | 32 | 4 | bdcef4f3e093c3646b639a189bbe93d6f4c40f3c | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.49e-06 | 187 | 32 | 4 | 09348f1e8bbbca8dca885461937b9b1dd248b034 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid_mast|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.49e-06 | 187 | 32 | 4 | 0f7a42c55997e34a0d20e492e16b03e91e965335 | |
| ToppCell | Control-Lymphocyte-B-B_intermediate|Control / Disease, Lineage and Cell Type | 9.49e-06 | 187 | 32 | 4 | 90c9b1a51539838323325f563be4adf5fdf1b38f | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_naive-B_naive-8|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 9.49e-06 | 187 | 32 | 4 | c10d6a774b3e83f64e47b9ad08f5d6b0dc60d163 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.49e-06 | 187 | 32 | 4 | 064730fa72f8637c3db3fc34d2e363d2b9a38f1d | |
| ToppCell | droplet-Liver-LIVER_NPC-30m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.69e-06 | 188 | 32 | 4 | 0aa8747c2931b0c91f6d78bb2db8fd8ede6dd559 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_B-B_cell-B_c01-TCL1A|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 9.69e-06 | 188 | 32 | 4 | d8decd9b5967873ca8320c2f9f07365f163c777f | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_atypical-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 9.69e-06 | 188 | 32 | 4 | ef05d2fb17fd427d46d454e67073e0e1b45bb24c | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.89e-06 | 189 | 32 | 4 | 1893765b1e3b306f1e133101c28403070a70c3c8 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.3.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.89e-06 | 189 | 32 | 4 | f01158bb15df3117fae1271bf8cf8c2501422671 | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid_mast|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.89e-06 | 189 | 32 | 4 | 96566f84c796d5b2e31f64090555f2b258f0c9f2 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_B-B_atypical|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 9.89e-06 | 189 | 32 | 4 | ebaf722738c71d5f33f72341f801c6880f4aee14 | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid_mast-Myeloid_Mast/Baso|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.89e-06 | 189 | 32 | 4 | 19b639bc6b35fe1d1079f60c8138aa946a95f3bf | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.89e-06 | 189 | 32 | 4 | b59cc66f7bb9b72895b775fbcf1ec1dc08610969 | |
| ToppCell | droplet-Liver-LIVER_NPC-30m-Endothelial|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.01e-05 | 190 | 32 | 4 | 25525fee1da8a808034d9c916159fd0b6b26bce8 | |
| ToppCell | droplet-Liver-LIVER_NPC-30m-Endothelial-endothelial_cell_of_hepatic_sinusoid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.01e-05 | 190 | 32 | 4 | a08c5929b05a4969852e351a93c4e4deb4c8d5b6 | |
| ToppCell | BLOOD--(2)_B_cell-(2)_Naive_B_cells|(2)_B_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 1.01e-05 | 190 | 32 | 4 | bde288cea27bbdc3ca05737a00fe30a0103a4c74 | |
| ToppCell | Mild/Remission-B_naive-11|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.03e-05 | 191 | 32 | 4 | ebb165096de301ba663703d1662d9413ea317867 | |
| ToppCell | cellseq-Immune-Hematopoietic-Granulocytic|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.05e-05 | 192 | 32 | 4 | 7af799b624167d1751c83e26b056be3692136c39 | |
| ToppCell | cellseq-Immune-Hematopoietic|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.05e-05 | 192 | 32 | 4 | a081624e81e6fca8bb8da58fc2809af451c7315c | |
| ToppCell | cellseq-Immune-Hematopoietic-Granulocytic-Mast/Basophil|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.05e-05 | 192 | 32 | 4 | b29d6b4bed4d55060586276973732461538752df | |
| ToppCell | COVID-19_Moderate-B_naive|World / disease group, cell group and cell class | 1.10e-05 | 194 | 32 | 4 | 1f81d618799e482a36dce528bba70f52cc69a901 | |
| ToppCell | medial-2-Hematologic-Basophil/Mast_1|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.10e-05 | 194 | 32 | 4 | 54d33508ce35b3d214214e4efbbb62f358667105 | |
| ToppCell | medial-Hematologic-Basophil/Mast_1-2|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.10e-05 | 194 | 32 | 4 | a89a03d4adebb9f644c27e199bff267180d8ef18 | |
| ToppCell | 10x_3'_v3-tissue-resident_(10x_3'_v3)-myeloid-myeloid_granulocytic-basophil|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.10e-05 | 194 | 32 | 4 | aca009b9f1f320c0a65ea16df6595d7ede0b1fda | |
| ToppCell | ILEUM-inflamed-(2)_B_cell-(2)_Naive_B_cells|(2)_B_cell / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 1.10e-05 | 194 | 32 | 4 | a89e67a40382600739be92e395bf47dd44aa4122 | |
| ToppCell | 3'-Broncho-tracheal-Immune_Myeloid_mast-Myeloid_Mast/Baso-mast_cell-Mast_cells-Mast_cells_L.1.4.0.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.10e-05 | 194 | 32 | 4 | 9d7f232ef5f27c28f325edfa6614f479013acbba | |
| ToppCell | medial-Hematologic-Basophil/Mast_1|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.10e-05 | 194 | 32 | 4 | ccfc142fe10b4ba16f3036f3f352983ee3e9c8ec | |
| ToppCell | 10x_3'_v2v3-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia/MHC-Z|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.12e-05 | 195 | 32 | 4 | 1f07502597e9476345b07f9f25aeeb6c1de13013 | |
| ToppCell | distal-Hematologic-Basophil/Mast_1-2|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.12e-05 | 195 | 32 | 4 | 4f83449fce3717518e2acbba1a4b3bea765c0bdb | |
| ToppCell | mild_COVID-19_(asymptomatic)-B_naive|World / disease group, cell group and cell class (v2) | 1.12e-05 | 195 | 32 | 4 | e763d9a431052c03cc6d514f2736506c6667e2be | |
| ToppCell | Mild/Remission-B_naive-8|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.12e-05 | 195 | 32 | 4 | 0a3221e4d1fa31a35868bdda0f0cc873c233b407 | |
| ToppCell | Bronchial-NucSeq|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations | 1.14e-05 | 196 | 32 | 4 | ab53c742866945545a92e2e61850d63c80d9a2a6 | |
| ToppCell | distal-2-Hematologic-Basophil/Mast_1|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.14e-05 | 196 | 32 | 4 | ad21706a281f0b105eb3979e3e47fe0cec6c527f | |
| ToppCell | distal-Hematologic-Basophil/Mast_1|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.14e-05 | 196 | 32 | 4 | 3df0f8fce94bd573f9f9dfeb06d5f68202627740 | |
| ToppCell | Sepsis-Leuk-UTI-Lymphocyte-B-B_intermediate|Leuk-UTI / Disease, condition lineage and cell class | 1.21e-05 | 199 | 32 | 4 | e3edf3bcb381dbcf0092bdc2ee93ba852d32af3f | |
| ToppCell | distal-Epithelial-Differentiating_Basal|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.21e-05 | 199 | 32 | 4 | 286d52f25120293620bdbfd62b832f08e118adf6 | |
| ToppCell | distal-Epithelial-Differentiating_Basal-1|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.21e-05 | 199 | 32 | 4 | a1b87c74fe3106ff8bf1c6ff4048d0c3d3fee7ba | |
| ToppCell | Control-Control-Lymphocyte-B-B_intermediate|Control / Disease, condition lineage and cell class | 1.21e-05 | 199 | 32 | 4 | ee6f07eec7edfe41d2f7fcb0b509ce00e99a6a95 | |
| ToppCell | Bronchial-10x5prime-Immune_Myeloid-Myeloid-Megakaryocyte|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.21e-05 | 199 | 32 | 4 | 6e7f7214317f2af2ba8523df9896f54b7294d58a | |
| ToppCell | Bronchial-10x5prime-Immune_Myeloid-Myeloid|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.21e-05 | 199 | 32 | 4 | 5f499595597c10857bba8272f62afe4d32d733ac | |
| ToppCell | distal-1-Epithelial-Differentiating_Basal|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.21e-05 | 199 | 32 | 4 | fe7d6f70fe337b91b0ad63ea33e5a714d2df87bd | |
| ToppCell | Bronchial-10x5prime-Immune_Myeloid-Mast_cell|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.24e-05 | 200 | 32 | 4 | 96540be0e906bbc626049a41978be3dc051d2024 | |
| ToppCell | COVID-19-COVID-19_Mild-Lymphocyte-B-B_naive|COVID-19_Mild / Disease, condition lineage and cell class | 1.24e-05 | 200 | 32 | 4 | e6a43eff47195e1d39530ad49ad908fc06a8b038 | |
| ToppCell | Bronchial-10x5prime-Immune_Myeloid-Mast_cell-Mast_cell|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.24e-05 | 200 | 32 | 4 | 41d7736427494cb30a2f23722ea2b86ff308cfd8 | |
| ToppCell | mild-B_naive|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.24e-05 | 200 | 32 | 4 | 222789b897e2a683bbfd1d00b6fd8705015d90df | |
| ToppCell | Biopsy_Control_(H.)-Immune-Mast_cells|Biopsy_Control_(H.) / Sample group, Lineage and Cell type | 1.24e-05 | 200 | 32 | 4 | 64bf125e0e5652a5a638a6bb32eb109cb0d5e232 | |
| ToppCell | Biopsy_IPF-Immune-Mast_cells|Biopsy_IPF / Sample group, Lineage and Cell type | 1.24e-05 | 200 | 32 | 4 | 44d07a3fa768ccdcd2a0483a41483d5c11c9111e | |
| ToppCell | mild-B_naive|mild / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.24e-05 | 200 | 32 | 4 | d0467cab6a42bf780aa49046bf3231ca161dc144 | |
| ToppCell | droplet-Heart-4Chambers-18m-Endothelial-nan|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.21e-05 | 86 | 32 | 3 | d20ec61a572b11641647358a546334b217c694f3 | |
| ToppCell | Frontal_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_2-Parm1|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 6.88e-05 | 111 | 32 | 3 | 1847dde68d349114286bc3317be6339666df4aa2 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Granulocytic-Mast_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 9.11e-05 | 122 | 32 | 3 | 032b5da8befcb1a159245f8d0c67f91795883ee0 | |
| ToppCell | Smart-seq2-tissue-resident_(Smart-seq2)-myeloid-myeloid_granulocytic-basophil|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 9.79e-05 | 125 | 32 | 3 | dec39707624529689f68dd46f910a71db5e91ab2 | |
| ToppCell | PBMC-Mild-Lymphocyte-B-B_cell-B_intermediate-B_activate-7|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.07e-04 | 129 | 32 | 3 | 58790c6eaa597b8e8209a0fbc970e9cffa10bca5 | |
| ToppCell | Severe-Myeloid-Mast-|Severe / Condition, Lineage, Cell class and cell subclass | 1.52e-04 | 145 | 32 | 3 | ce307d45425a5191882078f049f85477eec40b69 | |
| ToppCell | Severe-Myeloid-Mast|Severe / Condition, Lineage, Cell class and cell subclass | 1.52e-04 | 145 | 32 | 3 | e0bfd2ffdbd6c197ef0a04e983396ebd87ef7127 | |
| ToppCell | Children_(3_yrs)-Immune-mast_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.55e-04 | 146 | 32 | 3 | f7349d63bb47f1f22ced8ff514edc1c11bc782e7 | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_Invariant-Inducer-like-MAIT|GI_small-bowel / Manually curated celltypes from each tissue | 1.55e-04 | 146 | 32 | 3 | 1cb2e157222631e8915d89b255a843d16d7d99cc | |
| ToppCell | Mild/Remission-B_naive-4|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.61e-04 | 148 | 32 | 3 | dd5e1bc02824e743e1c030a303e32f27a359a8ca | |
| ToppCell | PBMC-Severe-Lymphocyte-B-B_cell-B_naive-B_naive-9|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.68e-04 | 150 | 32 | 3 | d9931507257c64ead4a53786e6822f51962c6015 | |
| ToppCell | Smart-seq2-bone_marrow_(Smart-seq2)-lymphocytic-B_lymphocytic-naive_B_cell|bone_marrow_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.71e-04 | 151 | 32 | 3 | 0f8f07e44c6edaf09574930b416fdce14d67095a | |
| ToppCell | 368C-Myeloid-Mast_cell|368C / Donor, Lineage, Cell class and subclass (all cells) | 1.74e-04 | 152 | 32 | 3 | faf30245a1690aaa27c7be0832797c340e4af4d7 | |
| ToppCell | 368C-Myeloid-Mast_cell-|368C / Donor, Lineage, Cell class and subclass (all cells) | 1.74e-04 | 152 | 32 | 3 | 519c9ed05fdaf420e42147ffae1dc05a7f86fdd4 | |
| ToppCell | Healthy-B_cell|Healthy / disease group, cell group and cell class | 1.78e-04 | 153 | 32 | 3 | 7f82cd61b3f1ebaee3e4bbf68ba858a67c2065e7 | |
| ToppCell | Adult-Immune-mast_cell-D122|Adult / Lineage, Cell type, age group and donor | 1.85e-04 | 155 | 32 | 3 | 7c9de0591d1bf756b8e268b278bbe10bd5415dcd | |
| ToppCell | renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Immune-Myeloid-Granulocytic-Mast_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 1.85e-04 | 155 | 32 | 3 | 231fbbbd6e6f9c86be7a15a9ec0804e6b9ab3b5f | |
| ToppCell | COVID-19-Mast_cells|COVID-19 / group, cell type (main and fine annotations) | 1.88e-04 | 156 | 32 | 3 | 159504d43421ee83b9ab484816333ae549c9c2fd | |
| ToppCell | COVID-19-Mast_cells-Mast_cells|COVID-19 / group, cell type (main and fine annotations) | 1.88e-04 | 156 | 32 | 3 | bc10b94673184ef384c6665b16a1209a8975a4f1 | |
| ToppCell | Adult-Immune-mast_cell-D231|Adult / Lineage, Cell type, age group and donor | 1.92e-04 | 157 | 32 | 3 | 4c63bb91f8708644e6ce2500072a4eeb8e1079dd | |
| ToppCell | Children_(3_yrs)-Immune-mast_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.92e-04 | 157 | 32 | 3 | ec185dbeabb67fd9ca85f71cab88463b60f9b1c1 | |
| ToppCell | Smart-seq2-spleen_(Smart-seq2)-lymphocytic-T_lymphocytic-mature_NK_T_cell|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.92e-04 | 157 | 32 | 3 | 3aa12913410925d577205cb6f1f5ae6bea20d93f | |
| ToppCell | Adult-Mesenchymal-chondrocyte|Adult / Lineage, Cell type, age group and donor | 1.99e-04 | 159 | 32 | 3 | 3f7305ee76447064b5c846c4f576360a2f7e0b7c | |
| ToppCell | 343B-Myeloid-Mast_cell-|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.03e-04 | 160 | 32 | 3 | a2f09b5955602819c8978f4372130c8ef915cd07 | |
| ToppCell | PBMC-Control-Lymphocyte-B-B_cell-B_naive-B_naive-11|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.03e-04 | 160 | 32 | 3 | 8396afbc7d919ba190863d50aa0ef8b9942a9866 | |
| ToppCell | PND07-Immune-Immune_Myeloid-Granulocytic-Mast|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.03e-04 | 160 | 32 | 3 | ca212634cf1875238071d1800ecdf34979a553fb | |
| ToppCell | 343B-Myeloid-Mast_cell|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.03e-04 | 160 | 32 | 3 | 133ecae0a894d9a0d49d58859623359096b6f030 | |
| ToppCell | PND07-Immune-Immune_Myeloid-Granulocytic-Mast-Mast_mature|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.03e-04 | 160 | 32 | 3 | 5d22c86deead516444349d495998e04586be4396 | |
| ToppCell | Adult-Immune-mast_cell|Adult / Lineage, Cell type, age group and donor | 2.07e-04 | 161 | 32 | 3 | 44f5c0256b3ce264a6c7b62740f32dcd45ee052d | |
| ToppCell | 5'-Parenchyma_lung-Epithelial-Alveolar_epithelium-type_II_pneumocyte-AT2-AT2_L.0.1.4.2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.07e-04 | 161 | 32 | 3 | 1f4614ae15bd2fc08e555cea4d0152c4a940d048 | |
| Drug | thymidine glycol monophosphate | 5.74e-06 | 3 | 32 | 2 | CID000165415 | |
| Drug | Brunfelsamidine | 1.15e-05 | 4 | 32 | 2 | CID005281683 | |
| Drug | uPA inhibitor | 1.22e-05 | 32 | 32 | 3 | CID000001746 | |
| Drug | GPGR | 2.06e-05 | 38 | 32 | 3 | CID000485268 | |
| Drug | Attpsa | 2.86e-05 | 6 | 32 | 2 | CID005487511 | |
| Drug | ioxaglate | 4.00e-05 | 7 | 32 | 2 | CID000003742 | |
| Drug | Telebrix | 4.00e-05 | 7 | 32 | 2 | CID000034536 | |
| Drug | daphnodorin C | 6.85e-05 | 9 | 32 | 2 | CID000072428 | |
| Drug | 1c5s | 8.55e-05 | 10 | 32 | 2 | CID000444753 | |
| Drug | AC1NUP69 | 8.55e-05 | 10 | 32 | 2 | CID005487154 | |
| Drug | Metaproterenol sulfate, orciprenaline sulfate [5874-97-5]; Up 200; 7.6uM; HL60; HT_HG-U133A | 1.02e-04 | 175 | 32 | 4 | 2485_UP | |
| Drug | Z-ala-ala-lys-mna | 1.04e-04 | 11 | 32 | 2 | CID005486901 | |
| Drug | pimaradiene | 1.04e-04 | 11 | 32 | 2 | CID000440909 | |
| Drug | daphnodorin A | 1.04e-04 | 11 | 32 | 2 | CID000072426 | |
| Drug | AC1NSU64 | 1.04e-04 | 11 | 32 | 2 | CID005316303 | |
| Drug | methylhistamine | 1.04e-04 | 11 | 32 | 2 | CID000000912 | |
| Drug | Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A | 1.07e-04 | 177 | 32 | 4 | 4652_DN | |
| Drug | bis(5-amidino-2-benzimidazolyl)methane | 1.25e-04 | 12 | 32 | 2 | CID000002386 | |
| Drug | NSC-648146 | 1.25e-04 | 12 | 32 | 2 | CID000372649 | |
| Drug | 4-amidinophenylpyruvic acid | 1.25e-04 | 12 | 32 | 2 | CID000151496 | |
| Drug | Elocom | 1.25e-04 | 12 | 32 | 2 | CID000123620 | |
| Drug | naphthol AS-D chloroacetate | 1.35e-04 | 71 | 32 | 3 | CID000160247 | |
| Drug | Beta-Escin [11072-93-8]; Up 200; 3.2uM; PC3; HT_HG-U133A | 1.47e-04 | 192 | 32 | 4 | 3807_UP | |
| Drug | Z-ARR-AFC | 1.48e-04 | 13 | 32 | 2 | CID000125067 | |
| Drug | Nk3201 | 1.48e-04 | 13 | 32 | 2 | CID000213050 | |
| Drug | Prednicarbate [73771-04-7]; Down 200; 8.2uM; PC3; HT_HG-U133A | 1.49e-04 | 193 | 32 | 4 | 5119_DN | |
| Drug | Cefepime hydrochloride [123171-59-5]; Up 200; 7.4uM; HL60; HT_HG-U133A | 1.55e-04 | 195 | 32 | 4 | 6159_UP | |
| Drug | Kaempferol [520-18-3]; Up 200; 14uM; HL60; HT_HG-U133A | 1.55e-04 | 195 | 32 | 4 | 6157_UP | |
| Drug | 2-propylpentanoic acid; Up 200; 500uM; MCF7; HG-U133A | 1.59e-04 | 196 | 32 | 4 | 347_UP | |
| Drug | DO 897/99; Up 200; 8.2uM; HL60; HG-U133A | 1.59e-04 | 196 | 32 | 4 | 1728_UP | |
| Drug | Indapamide [26807-65-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 1.62e-04 | 197 | 32 | 4 | 3859_UP | |
| Drug | Vigabatrin [60643-86-9]; Down 200; 31uM; MCF7; HT_HG-U133A | 1.62e-04 | 197 | 32 | 4 | 5415_DN | |
| Drug | Tubocurarine chloride pentahydrate (+) [6989-98-6]; Down 200; 5.2uM; MCF7; HT_HG-U133A | 1.62e-04 | 197 | 32 | 4 | 2887_DN | |
| Drug | Cotinine (-) [486-56-6]; Up 200; 22.6uM; MCF7; HT_HG-U133A | 1.62e-04 | 197 | 32 | 4 | 5611_UP | |
| Drug | raloxifene hydrochloride; Down 200; 0.1uM; MCF7; HG-U133A | 1.65e-04 | 198 | 32 | 4 | 202_DN | |
| Drug | AC1L8TZY | 1.65e-04 | 76 | 32 | 3 | CID000408095 | |
| Drug | ABPH | 1.72e-04 | 14 | 32 | 2 | CID000092377 | |
| Drug | AC1L9K4M | 1.99e-04 | 15 | 32 | 2 | CID000446820 | |
| Drug | FdTTP | 1.99e-04 | 15 | 32 | 2 | CID000162005 | |
| Drug | 5 alpha-androstan-3-one | 2.27e-04 | 16 | 32 | 2 | CID000102028 | |
| Drug | thymidine glycol | 2.27e-04 | 16 | 32 | 2 | CID003035041 | |
| Drug | (E)-4-aminohex-4-enoic acid | 2.27e-04 | 16 | 32 | 2 | CID005288385 | |
| Drug | methylimidazoleacetic acid | 2.57e-04 | 17 | 32 | 2 | CID000075810 | |
| Drug | H 17 | 2.57e-04 | 17 | 32 | 2 | CID000476867 | |
| Drug | LMWH | 2.83e-04 | 663 | 32 | 6 | CID000000772 | |
| Drug | 2-azetidinone | 2.89e-04 | 18 | 32 | 2 | CID000136721 | |
| Drug | NSC49103 | 3.58e-04 | 20 | 32 | 2 | CID000005251 | |
| Drug | A80a | 3.58e-04 | 20 | 32 | 2 | CID005487000 | |
| Drug | lead phosphate | 3.58e-04 | 20 | 32 | 2 | CID000024009 | |
| Disease | tartrate-resistant acid phosphatase type 5 measurement | 6.83e-06 | 4 | 32 | 2 | EFO_0020763 | |
| Disease | tryptase beta-2 measurement | 4.08e-05 | 9 | 32 | 2 | EFO_0008306 | |
| Disease | mood disorder | 8.82e-05 | 13 | 32 | 2 | EFO_0004247 | |
| Disease | urticaria | 2.14e-04 | 20 | 32 | 2 | EFO_0005531 | |
| Disease | coronary aneurysm | 6.63e-04 | 35 | 32 | 2 | EFO_1000881 | |
| Disease | basophil measurement | 1.94e-03 | 60 | 32 | 2 | EFO_0803539 | |
| Disease | biological sex | 1.96e-03 | 230 | 32 | 3 | PATO_0000047 | |
| Disease | neuroimaging measurement, brain volume measurement | 3.63e-03 | 286 | 32 | 3 | EFO_0004346, EFO_0006930 | |
| Disease | beverage consumption measurement | 3.67e-03 | 83 | 32 | 2 | EFO_0010088 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| AEGKAHLDFHCNEYG | 446 | Q5H9S7 | |
| NLHKLDGYYCDHEQG | 526 | O75078 | |
| VYLHDGHSCQDVDGY | 506 | O43184 | |
| HQELQGYYDNADKLH | 456 | Q8IY63 | |
| RDHDVYTGNCAHYQK | 421 | Q9UKU9 | |
| LHDEYCFYNGKTHRE | 86 | A2RUS2 | |
| KVLNHGYDDDNHDYI | 86 | Q9Y463 | |
| DDYLSYHELQGEIHC | 631 | Q9ULC6 | |
| FSHKEEYENGGHCLG | 131 | Q86XR2 | |
| GEPGCHYFEQLHYND | 1141 | Q86U86 | |
| DAGDCGQDHFHELYK | 531 | Q3T906 | |
| GKHYYEVSCHDQGLC | 131 | Q92499 | |
| GDCYYVLAKGDHNDS | 411 | Q02817 | |
| NVHTHYQEEKCYEDG | 466 | Q7Z7M0 | |
| YEQHPGDGHFYCLQH | 736 | Q8TDZ2 | |
| YEYKCGNGHCIPHDN | 3931 | P98164 | |
| YQELFDQGCHPYVDH | 71 | Q9BZM2 | |
| QNKHALGSHEYIQYC | 436 | O00750 | |
| YKELFYGHGDHLIDQ | 756 | Q7Z7M9 | |
| FHLCGDVDYKGGYRH | 551 | Q9UHN6 | |
| CEFPEIQHGHLYYEN | 271 | Q92496 | |
| YSKAQYNAGLCHEHG | 276 | Q14154 | |
| GHINGSHKEDLANCY | 151 | A1Z1Q3 | |
| HICDAKYHLGAYTGD | 186 | Q15661 | |
| HICDAKYHLGAYTGD | 186 | P20231 | |
| QKDSGNYLCHAVEHG | 641 | Q14563 | |
| LLEAHGDYGLRNDYH | 246 | Q9UIY3 | |
| LLNHKYYQDCSGGDR | 1426 | Q7KZ85 | |
| NLGKLYHEQGHYEEA | 611 | Q8N394 | |
| YGVTAYLCGHDHNLQ | 231 | P13686 | |
| YLCGHDHNLQYLQDE | 236 | P13686 | |
| EGEGKVCHNLGYAHY | 631 | Q96AY4 | |
| YHCAQKGHYGHECPE | 351 | Q8N3Z6 |